Search research articles
Contact Us
Filters
Showing results (811-820 of 842) with videos related to
Page
of 85
Sort By:
Nature Medicine
|
August 27, 2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Barry A Borlaug, Dalane W Kitzman, Melanie J Davies, et al.
The Canadian Journal of Cardiology
|
May 24, 2011
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care
Robert S McKelvie, Gordon W Moe, Anson Cheung, et al.
Circulation
|
April 28, 2021
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
Isabelle Johansson, Philip Joseph, Kumar Balasubramanian, et al.
European Heart Journal
|
August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
Javed Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JACC. Advances
|
May 30, 2023
Sex-Based Differences in Severe Outcomes, Including Cardiovascular Hospitalization, in Adults With COVID-19 in Ontario, Canada
Bahar Behrouzi, Atul Sivaswamy, Anna Chu, et al.
Lancet (London, England)
|
September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
Javed Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
The Canadian Journal of Cardiology
|
December 4, 2012
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure
Robert S McKelvie, Gordon W Moe, Justin A Ezekowitz, et al.
JACC. Advances
|
December 20, 2025
Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial
Caio A M Tavares, Luciano C P Azevedo, Patrícia O Guimarães, et al.
Lancet (London, England)
|
September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
Faiez Zannad, Christopher M O'Connor, Javed Butler, et al.
The New England Journal of Medicine
|
August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
Page
of 85
Search research articles
Search
Showing results (811-820 of 842) with videos related to
Sort By:
Page
of 85
Nature Medicine
|
August 27, 2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Barry A Borlaug, Dalane W Kitzman, Melanie J Davies, et al.
The Canadian Journal of Cardiology
|
May 24, 2011
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care
Robert S McKelvie, Gordon W Moe, Anson Cheung, et al.
Circulation
|
April 28, 2021
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
Isabelle Johansson, Philip Joseph, Kumar Balasubramanian, et al.
European Heart Journal
|
August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
Javed Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JACC. Advances
|
May 30, 2023
Sex-Based Differences in Severe Outcomes, Including Cardiovascular Hospitalization, in Adults With COVID-19 in Ontario, Canada
Bahar Behrouzi, Atul Sivaswamy, Anna Chu, et al.
Lancet (London, England)
|
September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
Javed Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
The Canadian Journal of Cardiology
|
December 4, 2012
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure
Robert S McKelvie, Gordon W Moe, Justin A Ezekowitz, et al.
JACC. Advances
|
December 20, 2025
Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial
Caio A M Tavares, Luciano C P Azevedo, Patrícia O Guimarães, et al.
Lancet (London, England)
|
September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
Faiez Zannad, Christopher M O'Connor, Javed Butler, et al.
The New England Journal of Medicine
|
August 25, 2023
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
Page
of 85